TLDR
- CRSP stock rose 9.06% on January 22, 2026, with no fresh negative news impacting the shares
- Wall Street analysts maintain bullish stance with average price target 32% above recent close of $54.73
- Bank of America lowered price target slightly from $90 to $89 but kept Buy rating
- Analysts expect continued sequential growth for Casgevy treatment through 2026
- BofA reduced 2026 revenue expectations for Casgevy but remains optimistic on pipeline
Crispr Therapeutics stock climbed 9.06% on January 22, 2026, closing at $54.73. The move came without any major company-specific news to explain the sudden price action.
The gene-editing company has been experiencing volatility in recent trading sessions. Despite the swings, analyst sentiment remains firmly in bullish territory.
Wall Street consensus points to an average price target sitting about 32% above the current trading price. That suggests the professional community sees room for further gains in the coming months.
Bank of America analyst Alec Stranahan made a small adjustment to his price target on January 22. He lowered his target from $90 to $89 while maintaining a Buy rating on the shares.
The modest reduction came as part of an earnings preview for the healthcare sector. Stranahan slightly reduced his 2026 revenue expectations for Casgevy, Crispr’s flagship treatment.
Casgevy Revenue Projections
Casgevy represents the company’s first commercial product. The treatment received regulatory approval for treating certain blood disorders.
Despite trimming near-term revenue forecasts, BofA still expects sequential growth throughout 2026. The analyst’s preview suggests confidence in the product’s commercial trajectory remains intact.
No negative news emerged to explain the earlier stock weakness. The recent climb appears to reflect renewed investor confidence in the development pipeline.
The stock has posted a year-to-date price gain of 4.37%. Average daily trading volume sits at approximately 2.01 million shares.
Technical Indicators and Market Position
Current market capitalization stands at $5.01 billion. Technical sentiment signals currently flash a Hold rating based on recent price action.
Multiple analysts have recently reiterated their ratings on CRSP stock. The pattern of maintained Buy ratings has helped support the share price recovery.
The 32% gap between current price and average analyst target represents one of the larger upside potentials in the biotech space. Whether that gap closes depends on execution and clinical progress.
Investor focus remains on Casgevy’s commercial rollout and pipeline advancement. The company’s gene-editing platform continues to attract attention from the research community.
Trading activity picked up during the January 22 session. Volume exceeded the typical daily average as buyers stepped in to push shares higher.
Several analysts have published earnings previews ahead of upcoming quarterly results. The previews generally maintain optimistic outlooks despite minor target adjustments.
BofA’s small price target reduction from $90 to $89 represents less than a 2% change. The maintained Buy rating carries more weight than the single-dollar adjustment.
Bank of America expects Casgevy to show continued sequential growth through 2026, with the analyst lowering expectations only slightly from previous forecasts.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
